P3 Health Partners - Class A opened higher at $2.78, compared with its previous close of $2.61. In the last trading session, the stock traded between $2.51 and $2.87. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in P3 Health Partners - Class A is now worth
$ 0.51
Resulting in a loss of
$ 99.49 (99.49%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
50%
Hold
50%
Sell
0%
Markets Today
Today's Change
+$0.12 (+4.41%)
Day High
$2.87
Day Low
$2.51
Day Open
$2.78
Prev Close
$2.61
Volume
44,367
1W Return
-33.55%
1M Return
-39.58%
3M Return
-77.83%
6M Return
-27.91%
1Y Return
-63.72%
Fundamentals
Market Cap ($ Mn)
11
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-16,607.69%
ROCE
-114.53%
EPS (TTM)
$0.12
Investment Returns
1 Week
-33.55%
1 Month
-39.58%
3 Months
-77.83%
6 Months
-27.91%
9 Months
31.64%
Financials
Quarterly
All values in $ Mn
355.8
Jun 25
345.3
Sep 25
384.8
Dec 25
386.4
Mar 26
386.4
Jun 26
396.3
Sep 26
Updates
11Nov
TD Cowen lowers P3 Health Partners price target to $4, maintains Hold
TD Cowen maintains a Hold rating on P3 Health Partners. Price target lowered from $13 to $4 by analyst Ryan Langston. Valuation cut reflects revised expectations for the company.
Yesterday
10Nov
P3 Health Partners FY26 guidance raised: Low end up to $1.525B
P3 Health Partners raised the low end of its FY26 sales guidance to $1.525 billion. The upper bound of the revenue forecast remains unchanged at $1.600 billion. The revised range sits against an analyst consensus estimate of $1.551 billion.
3 days ago
15Oct
P3 Health Partners files prospectus for resale of 15.6 million shares
P3 Health Partners filed a prospectus to resell up to 15,636,134 Class A Common Stock shares. The shares are issuable upon exercise of warrants from financing transactions spanning December 2022 to September 2026. Key investors include entities affiliated with VBC Growth SPV and Chicago Pacific Founders. Recent 2026 financings involved Series D and Series D-1 Cumulative Preferred Stock alongside warrants.
28 days ago
12Oct
P3 Health Partners appoints Dr. Michael Millie as Chief Clinical Officer
Dr. Michael Millie appointed as Chief Clinical Officer effective October 12, 2026. Awarded non-qualified stock option for 110,000 Class A shares as employment inducement. Option vests over four years at 25% per anniversary. Grant complies with Nasdaq Listing Rule 5635(c)(4) for stand-alone awards.
1mo ago
11Aug
P3 Health Partners Q2 EPS beats estimate, revenue tops $386 million
P3 Health Partners turned profitable in Q2 with $15.7M net income, beating EPS estimates. Revenue of $386.381M exceeded forecasts, driven by improved network economics.
3mo ago
11Aug
P3 Health Partners narrows FY2026 sales guidance to $1.500B-$1.600B
P3 Health Partners narrows FY2026 sales guidance to $1.500B-$1.600B, down from $1.500B-$1.650B. The revised midpoint of $1.550B exceeds the $1.524B market estimate, suggesting continued outperformance expectations despite reduced upside potential.
